An interventional study of Aqueous humor samples collection in Age Related Macular Degeneration, sponsored by Centre Hospitalier Universitaire de Nice. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Other
Anti-VEGF intravitreal injections are the treatment of choice in age-related macular degeneration (AMD). However 37% of patients are unresponsive or poorly responsive to these therapies. It is still not possible to foresee the patient's response to anti-VEGF injections. A poor response may be related to an activation of alternative pro-angiogenic pathways with over expression of many other pro-angiogenic cytokines.
The primary goal of this study is to measure the aqueous humor concentration of pro-angiogenic cytokines in AMD patients.
1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.
This study's enrollment of 100 is above the median of 51 across 985 interventional studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →Centre Hospitalier Universitaire de Nice is the lead sponsor of 709 studies on the registry; 176 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Procedure: Aqueous humor samples collection
In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
Change of pro-angiogenic cytokines concentration in the aqueous humor of patients with exudative AMD at 3 months
Time frame: At Month 3
Dose of VEGF in the aqueous humor of patients with exudative AMD
Time frame: At Day 0, Month 1, Month 2, Month 3
Dose of pro inflammatory cytokines in the aqueous humor of patients with exudative AMD
Time frame: At Day 0, Month 1, Month 2, Month 3
Measurement of visual acuity with Snellen chart
Time frame: At Day 0, Month 1, Month 2, Month 3
Measurement of visual acuity with ETDRS visual acuity chart
Time frame: At Day 0, Month 1, Month 2, Month 3
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nice